$Maravai LifeSciences (MRVI.US)$It is an American company li...

Revenue, operating profit, and net profit have all maintained rapid growth over the past 4 years. In the first three quarters of 2022, revenue increased 19%, operating profit increased 16.5%, and net profit increased 17.6%. The growth rate has declined, but it is still growing.

The balance ratio declined to 72% after rising from 73% to 88% in the past 4 years.

The balance sheet shows that the company's current assets increased sharply to 840 million, and long-term loans of 530 million yuan, accounting for 63% of net assets, and the leverage ratio is in the middle.

Net cash flow has greatly surpassed net investment over the past 5 years, and shareholder surpluses are high.

Currently, the price-earnings ratio is 8.9, and the price-earnings ratio is 7.7, you can choose (⭐️⭐️)